Universal Health Services, Inc. Class B

Based on a comprehensive review of Universal Health Services (UHS), the stock presents a compelling case for a Buy recommendation.

UHS is fundamentally sound, demonstrating strong profitability with improving margins, moderate leverage, and solid operational efficiency. While technical charts show recent price weakness and higher volatility, this has resulted in a deeply undervalued condition, with a very low P/E and a PEG ratio suggesting significant growth potential not reflected in the current price. The combination of stable financial health, an oversold technical position, and compelling valuation metrics indicates strong potential for price appreciation as market sentiment improves.

Investors should be prepared for near-term volatility given its beta above 1.0, but the current price level offers an attractive entry point for those bullish on the healthcare facilities sector.

*Note: This is not investment advice, for reference only.*

RockFlow Model Forecast: Three Scenarios for 2026

Based on the comprehensive analysis provided, here is a 12-month outlook for Universal Health Services (UHS):

The stock appears well-positioned for price appreciation, driven primarily by operational execution and margin recovery across its acute care and behavioral health divisions. Key catalysts include sustained demand for its services, continued operational efficiency gains, and potential stabilization of labor cost pressures. Potential risks remain industry-wide headwinds from labor inflation and regulatory scrutiny, alongside company-specific execution challenges in integrating recent acquisitions. While price targets are not available, the compelling valuation case presented suggests the current ~$206 price could rise if management successfully implements its margin improvement initiatives and navigates the challenging reimbursement environment.

Wall Street Consensus

Most Wall Street analysts are optimistic about Universal Health Services, Inc. Class B's 12-month outlook, with consensus target around $206.10, indicating expected upside potential.

Overall, UHS has investment potential but also faces challenges. Here are key factors to weigh before investing.

Of course, here is the technical analysis of UHS's price performance.

Overall Assessment UHS has experienced significant volatility and a challenging trend over the past three months, declining over 11%, though it has shown a slight recent recovery over the past month.

Short-term Performance The stock's 1.52% gain over the past month suggests a potential near-term stabilization or reversal attempt; however, this minor rebound is overshadowed by the substantial 11.13% drop over the last three months. While the stock has underperformed the broader market by over 15% during this three-month period, its positive Relative Strength figure indicates that its rate of decline has recently been less severe than the market's, hinting at a possible relative strength bottom.

Current Position Trading at $206.1, UHS is positioned in the lower-middle portion of its 52-week range ($152.33 to $246.33), approximately 42% above its low. Given the steep 3-month decline and a maximum drawdown of -21.72% over the past year, the stock appears to be in an oversold condition rather than overbought, suggesting potential for a technical rebound if bullish momentum returns.

Revenue & Profitability: UHS demonstrates strong profitability with a 9.9% net income margin in Q4 2025, showing improvement from 8.3% in the previous quarter. The company maintains solid operational profitability with an EBITDA margin of 17.5%, though revenue remained relatively flat quarter-over-quarter at approximately $4.5 billion. Operating income stability is evidenced by consistent operating margins around 11.5-11.6%.

Financial Health: The company maintains moderate leverage with a debt-equity ratio of 0.70 and total debt to capitalization of 41.3%, indicating reasonable financial leverage. UHS shows adequate liquidity with a current ratio of 1.05, though the cash ratio of 0.04 suggests limited immediate cash reserves relative to current liabilities. Strong interest coverage of 12.2x provides comfort regarding debt service capability.

Operational Efficiency: UHS achieves respectable returns with ROE of 6.1% and ROA of 2.9%, though these figures indicate moderate efficiency in capital utilization. The asset turnover of 0.29 suggests modest revenue generation relative to the asset base, while strong fixed asset turnover of 12.0 indicates effective utilization of property and equipment. The cash conversion cycle of 35 days demonstrates reasonable working capital management efficiency.

Based on the provided metrics, Universal Health Services (UHS) appears significantly undervalued based on traditional earnings multiples. The trailing and forward P/E ratios below 9 are exceptionally low, indicating a market price that is cheap relative to the company's earnings. Meanwhile, the remarkably low PEG ratio of approximately 0.34 strongly suggests the stock is undervalued when its earnings growth prospects are factored in, as a PEG below 1.0 typically indicates a potential bargain.

A direct peer comparison is not possible due to the unavailability of industry average data. However, the low P/E and PEG ratios are generally indicative of a valuation that is attractive on an absolute basis. A more definitive assessment of its relative value within the healthcare facilities sector would require benchmarking these metrics against industry peers to determine if this discount is typical or exceptional.

Volatility Risk: UHS exhibits moderate volatility risk, evidenced by a beta of 1.269, indicating it is expected to be about 27% more volatile than the broader market. This elevated beta is corroborated by a significant 1-year maximum drawdown of -21.72%, suggesting the stock has experienced substantial price declines from recent peaks, exposing investors to notable downside risk.

Other Risks: The absence of significant short interest implies that bearish sentiment is not a primary concern for UHS; however, investors should remain attentive to stock-specific factors. Key risks likely stem from operational and regulatory pressures within the healthcare sector, which can impact performance irrespective of market-wide trends. Liquidity is typical for a large-cap stock but should be monitored in volatile market conditions.